1,281 reports of this reaction
6.4% of all NADOLOL reports
#1 most reported adverse reaction
DRUG INEFFECTIVE is the #1 most commonly reported adverse reaction for NADOLOL, manufactured by Alembic Pharmaceuticals Inc.. There are 1,281 FDA adverse event reports linking NADOLOL to DRUG INEFFECTIVE. This represents approximately 6.4% of all 20,171 adverse event reports for this drug.
Patients taking NADOLOL who experience drug ineffective should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG INEFFECTIVE is moderately reported among NADOLOL users, representing a notable but not dominant share of adverse events.
In addition to drug ineffective, the following adverse reactions have been reported for NADOLOL:
The following drugs have also been linked to drug ineffective in FDA adverse event reports:
DRUG INEFFECTIVE has been reported as an adverse event in 1,281 FDA reports for NADOLOL. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG INEFFECTIVE accounts for approximately 6.4% of all adverse event reports for NADOLOL, making it one of the most commonly reported side effect.
If you experience drug ineffective while taking NADOLOL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.